Neil Woodford has said the "crowded consensus" that he has previously warned is prevalent in stockmarkets is about to unwind, and he has started to see evidence of this in the share price performance of the companies he holds.
In a video released yesterday, the star manager described his disappointment that the share price of Prothena, a company he has a 30% stake in, tumbled 70% after it abandoned spending on a treatment for AL amyloidosis, a rare disease that can lead to organ failure, after it failed late-stage trials. However, Woodford said he will continue to back the company and added his calls of a "crowded consensus" in the stockmarkets are about to be recognised. His funds, including the £6.7bn Woodford Equity Income fund, have seen a number of significant share price falls including plunges in Ast...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
